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Abstract
Purpose: Non-white patients are underrepresented in left atrial appendage occlusion
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(LAAO) trials, and racial disparities in LAAO periprocedural management are unknown.
Methods: We assessed sociodemographics and comorbidities of consecutive patients
at our institution undergoing LAAO between 2015 and 2020, then in adjusted analyses, compared procedural wait time, procedural complications, and post-procedure
oral anticoagulation (OAC) use in whites versus non-whites.
Results: Among 109 patients undergoing LAAO (45% white), whites had lower
CHA2 DS2 VASc scores, on average, than non-whites (4.0 vs. 4.8, p = .006). There was
no difference in median time from index event (IE) or initial outpatient cardiology
encounter to LAAO procedure (whites 10.5 vs. non-whites 13.7 months, p = .9; 1.9 vs.
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1.8 months, p = .6, respectively), and there was no difference in procedural complications (whites 4% vs. non-whites 5%, p = .33). After adjusting for CHA2 DS2 VASc score,
OAC use at discharge tended to be higher in whites (OR 2.4, 95% CI [0.9-6.0], p = .07).
When restricting the analysis to those with prior gastrointestinal (GI) bleed, adjusting
for CHA2 DS2 VASc score and GI bleed severity, whites had a nearly five-fold odds of
being discharged on OAC (OR 4.6, 95% CI [1-21.8], p = 0.05). The association between
race and discharge OAC was not mediated through income category (total mediation
effect 19% 95% CI [-.04-0.11], p = .38).
Conclusion: Despite an increased prevalence of comorbidities amongst non-whites,
wait time for LAAO and procedural complications were similar in whites versus nonwhites. Among those with prior GI bleed, whites were nearly five-fold more likely to be
discharged on OAC than non-whites, independent of income.
KEYWORDS

atrial fibrillation, cerebrovascular accident, left atrial occlusion device, mediation analysis, racial
disparities, Watchman
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1

INTRODUCTION

TEE and fluoroscopic guidance. Device implantation procedures
were performed jointly by an interventional cardiologist and cardiac

Atrial fibrillation (AF) is the most common cardiac arrhythmia in the

electrophysiologist (five total implanting physicians at our institution),

United States, and its prevalence is projected to increase as the pop-

with an advanced fellow in training present during the majority of pro-

ulation ages.1 It affects approximately 1% of the United States popula-

cedures. Safety outcomes related to device implantation were defined

tion and is the most common cause of embolic stroke.2–4 The primary

as cardiac perforation, pericardial effusion, cardiac tamponade, stroke,

treatment strategy for stroke risk reduction is with chronic oral antico-

myocardial infarction, or death during the index hospitalization. There

agulation (OAC).5 Left atrial appendage occlusion (LAAO) has emerged

was no protocol for the use of anticoagulation aside from what was

as a stroke risk reduction strategy for patients in whom long-term OAC

done in prior clinical trials.7 Post-procedural anticoagulation regimen

use is contraindicated and been demonstrated to be non-inferior to

was determined on an individual basis according to the treating

OAC.6–9

physician.

LAAO by Watchman (Boston Scientific, St. Paul, Minnesota,

Normally distributed continuous variables were reported as

USA) has emerged as the most common non-surgical LAAO strategy in

means ± standard deviation and were compared using Student’s

the United States.10
Despite blacks with AF having a greater risk of embolic stroke,11

t-test. Categorical variables were reported as proportions and were

and being more likely to have subtherapeutic anticoagulation and

compared using the chi-square test. Income data were obtained by

higher risk of hemorrhage when treated with warfarin for stroke

publicly available median income figures by zip code, and incorpo-

prevention,12 large trials examining the benefits of Watchman implant

rated into the mediation analysis as a binary variable of above or

have markedly underrepresented blacks, who comprise less than 2% of

below the poverty line.23 Times from IE and cardiology referral to

study

cohorts.6,7,9,13

This may be, in part, due to a diminished referral

device implant were reported as medians with interquartile range and

pattern in blacks relative to whites for LAAO14 and that whites may be

comparisons between groups were performed using Cox regression

more likely to embrace new therapeutic medical technologies.15 These

models. Adjustments in time from IE and cardiology referral to device

findings reflect a general trend in racial disparities in access to med-

implant, and post implantation anticoagulation regimen were made for

ical care, whereby non-white and indigent patients face greater bar-

CHA2 DS2 VASc score. Adjustments for regressions comparing post-

riers to continuity of care and medical care,16–18 including advanced

procedural anticoagulation regimen were made for CHA2 DS2 VASc

therapies such as percutaneous coronary intervention,19 and coronary

score and severity of gastrointestinal (GI) bleed (severe vs. less than

bypass and valvular surgery.14,20,21

severe). Variables included in the CHA2 DS2 VASc score were not

Given the diverse socio-demographics in the United States,

individually adjusted for to avoid statistical redundancy and reduction

understanding disparities in the delivery of care across races and

in power. GI bleed was defined as severe if the patient required blood

socioeconomic groups is essential. In white versus non-white patients

transfusion, or Type 3 bleed according to the Bleeding Academic

undergoing LAAO, we compared patient socioeconomic and med-

Research Consortium definition for bleeding.24 Income was treated as

ical characteristics, examined differences in procedural wait time,

a mediator on the forward pathway from race to anticoagulation use

procedural complications, post-LAAO anticoagulation regimen, and

on discharge.25 Its effect on the relationship between race and OAC

post-procedural follow-up parameters.

at discharge was assessed using maximum likelihood estimation in a
structural equation model. We also examined whether there was any
association in the OAC prescription pattern in those with ESRD versus

2

METHODS

non-ESRD patients using a logistic regression model. A two-tailed
p-value of < .05 was considered statistically significant. All analyses

We identified consecutive patients undergoing LAAO (Watchman) at

were performed using STATA 15.1 Statistical Software (StataCorp,

our urban medical center between May 2015 and March 2020 through

College Station, Texas, USA).

retrospective review of our electronic medical record, and patients
were entered into an institutional clinical registry. In white versus nonwhite patients, we compared socio-demographic factors, medical co-

3

RESULTS

morbidities, procedural wait time from index event (IE), defined as
time from event when a patient was deemed to be a poor candidate

We identified 109 consecutive patients undergoing LAAO during

for long-term anticoagulation, and cardiology encounter to implant

the study period. Patient characteristics, including comorbidities and

procedure, procedural complications, post-procedure anticoagulation

socio-demographics, are shown in Table 1. Non-white patients (n = 60,

regimen, adherence to protocoled 45-day follow-up transesophageal

55%) were mostly black (n = 42, 39% of total cohort), and of simi-

echocardiogram (TEE), and prevalence of LAAO leak.

lar age to white patients. Overall, non-white patients were sicker than

The Watchman implant procedure has been previously described.22

white patients, more frequently reported a prior history of stroke,

Pre-procedural left atrial appendage sizing was done via cardiac

and had higher average CHA2 DS2 VASc and HAS-BLED scores com-

computed tomography or TEE, and subsequently confirmed intra-

pared to whites. The cohort overall had a high prevalence of poverty

procedurally by TEE. The implantation procedure was done under

(n = 40, 38%), and non-white patients were markedly more likely to be
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TA B L E 1

Baseline characteristics in white versus non-white patients

Age, year

White (N = 49)

Non-white (N = 60)

P-value

75.3 ± 7.6

72.5 ± 9.8

.10

25 (42)

.16

Sex, female

27 (55)

Race/ethnicity
White
African American
Hispanic
AsianOther

49 (100)

Hypertension

38 (78)

50 (83)

.45

Diabetes mellitus

19 (39)

32 (53)

.13

42 (70)15 (25)
2 (3)1 (2)

Cerebrovascular accident

7 (14)

26(43)

.001

Coronary artery disease

16 (41)

19 (42)

.91

Peripheral vascular disease

9 (18)

10 (17)

.82

Congestive heart failure

9 (18)

29 (48)

.001

End stage renal disease

0 (0)

12 (20)

<.001

AF pattern
Paroxysmal
Persistent
PermanentUnknown

29 (59)7 (14)
10 (20)3 (6)

36 (60)7 (12)
9 (15)8 (13)

.38

CHA2DS2VASc Score (continuous)

4.06 ± 1.27

4.80 ± 1.47

.01

CHA2DS2VASc Score (categorical)
1
2
3
4
5
6
78

1 (2)5 (10)
10 (20)
13 (27)
14 (29)
6 (12)
0 (0)0 (0)

0 (0)3 (5)
7 (12)
20 (33)
9 (15)
13 (22)
6 (10)2 (3)

.05

3.47 ± 0.84

4.18 ± 0.95

<.001

1 (2)46 (94)1 (4)

6 (10)51 (85)3 (5)

.23

51,859 ± 25,241

29,714 ± 12,038

<.001

7 (15)

33 (55)

<.001

Indication for Watchman
Major bleeding
Labile INR
Fallsa Bruisingb Otherb

37 (76)2 (4)
4 (8)
4 (8)2 (4)

53 (88)0 (0)
2 (3)
0 (0)5 (8)

.04

Type of bleeding
GI bleed
Intracranial hemorrhage
Epistaxis
HematuriaOther

23 (62)3 (8)
3 (8)
5 (14)3 (8)

38 (70)5 (9)
6 (11)
0 (0)5 (9)

.09

HAS-BLED Score (continuous)
Insurance provider
Medicaid
MedicarePrivate
Mean annual income (dollars)
Below poverty line

Values are in N (%), mean ± SD. The p values are based on t-tests for continuous variables and chi-square tests for dichotomous variables.
CHA2 DS2 VASc Score: sum of congestive heart failure (+ 1), hypertension (+ 1), age 65 to 74 years (+ 1) and > 75 years (+ 2), female sex (+ 1), diabetes mellitus
(+ 1), previous stroke/transient ischemic attack (+ 2), and vascular disease (+ 1).
HAS-BLED Score: sum of (+ 1 for each) hypertension, renal disease, liver disease, previous stroke/transient ischemic attack, prior major bleeding or disposition to bleeding, labile INR if on warfarin, age > 65 years, medication use predisposing to bleeding, alcohol consumption of > 7 drinks/week.
Abbreviations: INR, international normalized ratio; AF, Atrial fibrillation.
a
In these patients, oral anticoagulation was felt unsafe and therefore Watchman was offered.
b
These patients refused lifelong oral anticoagulation and therefore Watchman was offered.
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TA B L E 2 Comparisons of time to implant, procedural complications, post LAAO implant anticoagulation use, and adherence to 45-day follow
up transesophageal echocardiogram between white and non-white patients

Time from IE to implant, months
Time from cardiology referral to implant, months

White

Non-white

p-value

10.5 (5.7-39.7)

13.7 (5.1-38.9)

.9a , 1b

1.9 (1.1-4.0)

1.8 (1.0-3.1)

.9a , .6b

40 (81.6)
9 (18.4)

40 (66.7)
20 (33.3)

.08c , .05d

OAC
Warfarin
DOAC

22 (55)
18 (45)

20 (51)
19 (49)

.74e

Complications
pericardial effusion
cardiac perforation
tamponade

2 (4)
2 (100)
0 (0)
0 (0)

3 (5)
1 (33)
1 (33)
1 (33)

.33e

51 (88)

.58e

Discharge anticoagulation
OAC
DAPT

Follow up TEE ≤ 45 days

42 (91)

Values are in n (%), time data are in median (IQR1-IQR3).
Abbreviations: DOAC, direct oral anticoagulants; OAC, oral anticoagulants; DAPT, dual antiplatelet therapy; TEE, transesophageal echocardiogram; GI, gastrointestinal; LAAO, Left atrial appendage occlusion; IE, index event.
a
p values based on a univariable Cox regression model.
b
p values based on a multivariable Cox regression model adjusting for CHA2DS2VASc score.
c
p value is based on a univariable logistic regression model.
d
p value is based on a multivariable logistic regression model, restricted to those with prior GI bleed, adjusting for CHA2 DS2 VASc and GI bleed severity.
e
p value is based on chi-square test.

F I G U R E 1 Odds of oral anticoagulation use in whites versus non-whites after LAAO, stratified by indication. White patients are the referent
group. Unadjusted analyses were conducted using univariable logistic regression models and adjusted analyses were conducted using
multivariable logistic regression models * adjusting for CHA2 DS2 VASc score or + CHA2 DS2 VASc score and GI bleed severity
in poverty than whites. There was no significant difference between

cance (unadjusted OR 2.2, 95% CI [0.9-5.5], p = .08; adjusted OR 2.4,

the two groups in terms of medical insurance providers, with the vast

95% CI [0.9-6.0], p = .07). However, when restricting the analysis to

majority of patients having Medicare. When comparing blacks and His-

those with prior GI bleed as the indication for LAAO, after adjusting

panics, there was no significant difference in the baseline characteris-

for CHA2 DS2 VASc and severity of GI bleed, whites were nearly five

tics between the two groups (Supplementary Table S1). Compared to

times more likely to be discharged on OAC versus dual antiplatelet

whites, non-white patients had similar times from IE, the majority of

therapy compared to non-whites (unadjusted OR 3.1, 95% CI [0.76-

which were GI bleeds, and cardiology referral appointment to device

12.4], p = .1; adjusted OR 4.6, 95% CI [1-21.8], p = .05) (Figure 1). In

implant (Table 2).

those who were discharged on OAC, warfarin was prescribed for 22

All patients had successful LAAO. Five patients experienced a proce-

(55%) of white patients compared to 20 (50%) of non-white patients

dural complication, all of which were pericardial effusions. One patient

and there was no statistical difference between the two groups

required pericardial drainage due to tamponade. One patient under-

(p = .74).

went emergent surgical intervention due to cardiac perforation. Of the

In our study cohort, there were 12 patients with end stage renal dis-

five patients, two were white, and three were non-white; there was no

ease (ESRD), all of whom were black. Most of our ESRD patients, 67%

difference in complication rates between groups (whites 4% vs. non-

(eight patients) were discharged on OAC regimen. There was no sig-

whites 5%, p = .33).

nificant difference in the use of OAC when comparing ESRD patients

After adjusting for CHA2 DS2 VASc score, white patients were twice

versus non-ESRD patients (OR 1.4, 95% CI [0.4-5.2], p = .6).

as likely as non-white patients to be discharge on OAC rather than dual

In examining the extent to which income may mediate the racial dif-

antiplatelet therapy. This observation did not meet statistical signifi-

ference on OAC use at discharge, income did not statistically influence
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the relationship between race and discharge anticoagulation regimen

whites once they had been referred. Impoverished patients often have

(p = .38). Income only accounted for 19% (95% CI [- 0.04-0.11]), p = .38)

more obstacles to advanced forms of therapy such as LAAO,16–18 and

of the total effect of race on discharge OAC regimen.

race-related healthcare disparities in the United States persist after

Excluding patients who had their 45-day follow-up TEE postponed

accounting for income.35 Longer procedural wait times have corre-

due to the SARS-CoV-2 pandemic (white, n = 3; non-white, n = 2), pro-

lated with worse outcomes and lower patient satisfaction.36,37 Dispar-

tocoled 45-day follow-up TEE was done within 45 days in 91% of whites

ities in procedural wait times along racial lines have been reported.38

and 88% of non-whites (p = .58). Three patients had peri-device leak

However, we did not observe a significant difference LAAO wait time

of > 5 mm at the follow-up TEE, all of whom were non-white (p = .1).

according to race, with any difference perhaps mitigated by prevalent
relative uniformity in health insurance provider in our population, or
other system factors related to serving an impoverished community.

4

DISCUSSION

While there was no difference in procedural wait times between
whites and non-whites, most patients across races had government

In the context of national racial disparities in medical care and

based medical coverage (i.e. Medicare or Medicaid). As there is an inter-

underrepresentation of minority races and ethnicities in major LAAO

play between race and insurance that contributes to access to care,39

trials,6,7,9,13

we examined a racially diverse group of consecutive

it may be that insurance coverage serves as an equalizer in leveling

patients undergoing LAAO procedures at our urban institution. We

procedural wait times. It may also be that at a hospital such as ours

compared patient comorbid and socio-demographic characteristics,

where the large majority of patients are minorities and on government

procedural wait times, complications, discharge medical regimen, and

based medical coverage, the system is more adept in navigating the

follow up TEE results in white versus non-white patients. Although

challenges of progressing from hospitalization to outpatient referral

non-white patients were markedly sicker and more frequently living in

to elective procedural intervention. It is provocative that in some con-

poverty, procedural wait times and complications between whites and

texts, there are differences in wait time across race or income,38,40 but

non-whites did not significantly differ. However, post-procedural med-

in other scenarios, as in the present study, this is not the case. Whether

ical management demonstrated more prevalent use of OAC in whites

these differences in socioeconomic disparities are related to bias or an

than in non-whites, particularly in a subset of patients with a history of

effect of the degree of heterogeneity in patient mix, or something else,

GI bleed.

is unknown. In a population with greater heterogeneity in insurance

AF is more common in whites compared with non-whites,26–28

coverage, and thus more variability in prior authorization practices and

despite a greater incidence of risk factors for AF amongst non-

reimbursement policies, differences in procedural wait times may be

whites, who also suffer greater morbidity associated with AF, including

exaggerated.

stroke.11,29 As LAAO is the preferred alternative for stroke prevention

Despite there being no difference between race groups in proce-

in patients with a contraindication to OAC understanding racial dispar-

dural wait times, it is notable that the overall median wait times from

ities in those undergoing LAAO is critical.

IE to LAAO procedure and cardiology referral to LAAO procedure
disparity,30

we found that

were 13.5 and 1.85 months, respectively. This represents a period of

non-white patients had more medical co-morbidities at baseline than

time, off of OAC, prior to LAAO, during which patients were vulnera-

whites. Hispanics had a similar prevalence of co-morbidities when com-

ble to cardio-embolic events. Relative uniformity of insurance coverage

pared to black patients. Given that patient co-morbidity is strongly

across patients, urban geography, and service of an underserved com-

associated with differences in race and ethnicity, the higher risk of pro-

munity may be equalizers in procedural wait times, but may be in and

cedural complications in sicker patients may disproportionately affect

of themselves be tied to delays in care.

Consistent with national trends in racial

minority races and ethnicities.31,32 In fact, our racially diverse popula-

We found no difference in acute procedural complications in LAAO

tion had more co-morbidities compared to the patient cohorts in the

when comparing whites versus non-whites. The incidence of procedu-

PROTECT AF and PREVAIL trials with regard to congestive heart fail-

ral complications across racial and socioeconomic lines has been shown

ure (34.9% vs. 23.4% and 26.8%, respectively), stroke (30.3% vs. 17.7%

in catheter based and cardiac procedures,41,42 although is not a uni-

In addition

form observation in other procedural populations.43 A recent analysis

to being sicker than whites, non-white patients in our study were more

of the National Inpatient Sample to assess racial and ethnic disparities

likely to be impoverished, and may be more representative of urban

in the utilization of structural heart disease interventions in the United

populations in the United States.33 The morbidity of patients in our

States, including LAAO, revealed that while TAVR and LAAO may be

study was similar to that which was found examining LAAO patients

under-utilized in minorities, outcomes across racial lines are similar.14

among different racial groups in the National Inpatient Sample, sug-

In our racially diverse population of consecutive patients undergoing

gesting that our population may be more representative of what is

LAAO, there was no difference in acute complications after LAAO,

observed outside clinical trials.14

despite an increased prevalence of co-morbidities. Our overall compli-

and 27.5%) and diabetes (46.8% vs. 24.4% and

33.8%)..6,7,9

While it has been reported that blacks may have reduced access
to LAAO,14,34 we found that non-whites, who were also poorer than
whites in our study, had similar wait times for LAAO when compared to

cation rate is similar to that of previous published studies of LAAO with
Watchman.6,7
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Watchman implantation guidelines stipulate that OAC is recommended for the 45 days after LAAO to protect against device-related

may nonetheless be generalizable. The lack of significant difference in
the

thrombus as endothelialization over the occlusion device occurs with
no difference in the safety profile when using Direct Oral Anticoagulation (DOAC) or warfarin.7,44 However, in a multicenter prospective

5

CONCLUSION

trial, the use of OAC was contraindicated in 73% of patients undergoing Watchman placement,45 although the threshold for when OAC

Significant differences in baseline patient characteristics and co-

is “contraindicated” is somewhat subjective and often incorporates

morbidities between white and non-white patients undergoing LAAO

patient preference.46 When discharging a patient in whom OAC is

implantation do exist. However, these differences did not translate

contraindicated after Watchman implant, dual antiplatelet therapy is

into longer procedural wait times, acute procedural complications, or

suggested.47

In our analysis, the majority of the patients were dis-

disparate results on follow-up 45-day TEE. However, upon discharge

charged on OAC. However, there was a trend toward more preva-

immediately after LAAO, OAC versus dual antiplatelet therapy is more

lent use of dual antiplatelet therapy in non-white patients when com-

common in whites versus non-whites, a relationship that is markedly

pared to whites. When restricting the analysis to patients with prior

more pronounced in those with prior GI bleed and independent of level

GI bleed, in whom the decision to discharge on OAC versus dual

of income.

antiplatelet therapy is most pertinent, whites were nearly three-fold
more likely to be discharged on OAC than non-whites (non-significant).
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